Download Free Sample Report

The global Generic Injectables market was valued at US$ 160.3 billion in 2023 and is projected to reach US$ 222.6 billion by 2030, at a CAGR of 5.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report studies the Generic Injectables market, covering market size for segment by type (Small Molecules, Large Molecules, etc.), by application (Oncology, Anesthesia, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Hospira (Pfizer), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals, Dr. Reddy?s Laboratories, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).

This report provides detailed historical analysis of global market for Generic Injectables from 2018-2023, and provides extensive market forecasts from 2024-2032 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Generic Injectables market.

Leading Players of Generic Injectables including:

• Hospira (Pfizer)
• Fresenius Kabi
• Sandoz (Novartis)
• Hikma Pharmaceuticals
• Dr. Reddy?s Laboratories
• Grifols
• Nichi-Iko Group (Sagent)
• Teva Pharmaceutical
• Auromedics
• Sanofi
• Claris Injectables (Baxter)
• Gland Pharma
• Endo International
• Lupin Pharmaceuticals

Market split by Type:

• Small Molecules
• Large Molecules

Market split by Application:

• Oncology
• Anesthesia
• Anti-Infectives
• Parenteral Nutrition
• Cardiovascular Diseases

Market split by Sales Channel:

• Direct Channel
• Distribution Channel

Market split by Region/Country:

• North America (United States and Canada)
• Europe (Germany, UK, France, Italy, Spain, and Russia, etc.)
• Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia, etc.)
• South America (Brazil, Mexico, and Argentina, etc.)
• Middle East & Africa (Turkey, UAE, Saudi Arabia, and South Africa, etc.)

If you have any special requirements, please let us know and we can provide you the customized report as you want.